TriNetX Dataworks-USA: Overview of a Multi-Purpose, De-Identified, Federated Electronic Health Record Real-World Data and Analytics Network and Comparison to the US Census.

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Ellen Stein, Matthias Hüser, E Susan Amirian, Matvey B Palchuk, Jeffrey S Brown
{"title":"TriNetX Dataworks-USA: Overview of a Multi-Purpose, De-Identified, Federated Electronic Health Record Real-World Data and Analytics Network and Comparison to the US Census.","authors":"Ellen Stein, Matthias Hüser, E Susan Amirian, Matvey B Palchuk, Jeffrey S Brown","doi":"10.1002/pds.70198","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases. The purpose of this study is to describe the Network's characteristics, as well as its generalizability to the US population, particularly the healthcare-seeking population.</p><p><strong>Methods: </strong>Using the Dataworks-USA Network, a large, regularly updated data network containing de-identified patient electronic health record (EHR) information from across the United States, basic demographics were summarized and compared to the US Census Bureau International Database (IDB) 2022 data and the National Cancer Institute's version of the Census Bureau's U.S. County Population Data for 2022 to examine the generalizability of the Network.</p><p><strong>Results: </strong>Patients in the Dataworks-USA Network are approximately 5 years older than the Census, and the Network has a larger proportion of female patients. The Network has a lower proportion of patients identified as Asian and White race, and a higher proportion who identify as other relative to the Census; other races are similar between the two data sources (< 1% difference). Regionally, Dataworks-USA has a smaller proportion of patients in all race categories compared with the Census due to the larger proportion of patients of Unknown or Other race.</p><p><strong>Conclusions: </strong>TriNetX's Dataworks-USA Network provides a robust data source for many use cases and is broadly generalizable to the US population, particularly the healthcare-seeking population, with differences related to the underlying nature of the data sources.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 9","pages":"e70198"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414656/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70198","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases. The purpose of this study is to describe the Network's characteristics, as well as its generalizability to the US population, particularly the healthcare-seeking population.

Methods: Using the Dataworks-USA Network, a large, regularly updated data network containing de-identified patient electronic health record (EHR) information from across the United States, basic demographics were summarized and compared to the US Census Bureau International Database (IDB) 2022 data and the National Cancer Institute's version of the Census Bureau's U.S. County Population Data for 2022 to examine the generalizability of the Network.

Results: Patients in the Dataworks-USA Network are approximately 5 years older than the Census, and the Network has a larger proportion of female patients. The Network has a lower proportion of patients identified as Asian and White race, and a higher proportion who identify as other relative to the Census; other races are similar between the two data sources (< 1% difference). Regionally, Dataworks-USA has a smaller proportion of patients in all race categories compared with the Census due to the larger proportion of patients of Unknown or Other race.

Conclusions: TriNetX's Dataworks-USA Network provides a robust data source for many use cases and is broadly generalizable to the US population, particularly the healthcare-seeking population, with differences related to the underlying nature of the data sources.

Abstract Image

Abstract Image

Abstract Image

TriNetX Dataworks-USA:多用途、去识别、联邦电子健康记录真实世界数据和分析网络概述,并与美国人口普查进行比较。
导读:许多临床数据网络通常专注于单个用例或疾病。相比之下,TriNetX Dataworks-USA网络包含现实世界的临床信息,可以应用于多个研究问题和用例。本研究的目的是描述网络的特点,以及其对美国人口的普遍性,特别是寻求医疗保健的人口。方法:使用Dataworks-USA网络(一个包含来自美国各地的去身份化患者电子健康记录(EHR)信息的大型定期更新数据网络),总结基本人口统计数据,并将其与美国人口普查局国际数据库(IDB) 2022年数据和国家癌症研究所版本的人口普查局美国县人口数据进行比较,以检查该网络的普遍性。结果:Dataworks-USA网络的患者年龄比普查局大5岁左右,且网络中女性患者比例较大。该网络中被认定为亚洲和白人的患者比例较低,而相对于人口普查,被认定为其他种族的患者比例较高;其他种族在两个数据源之间是相似的(结论:TriNetX的Dataworks-USA Network为许多用例提供了一个健壮的数据源,并且可以广泛地推广到美国人口,特别是寻求医疗保健的人口,差异与数据源的基本性质有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
7.70%
发文量
173
审稿时长
3 months
期刊介绍: The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信